[ad_1]
This means that the Vaxzevria vaccine will continue to be available to all residents over 18 years of age, and Lithuania remains one of the ten countries in the European Union that do not apply additional age restrictions to this vaccine. Germany has already decided to lift the additional restrictions, as it had previously only administered the vaccine to people over the age of 60, according to a SAM press release.
The EVA also does not recommend the age limit for vaccination with Vaxzevria, which concluded that the benefits of the vaccine in fighting the spread of COVID-19 continue to outweigh the risk of potential side effects in adults of all ages. The Agency found that Vaxzevria was effective in preventing hospitalization, intensive care unit treatment, and death from COVID-19. As the number of infections increases, so do the benefits of the vaccine, according to the report.
In Lithuania, the incidence of COVID-19 disease in 14 days today reaches 583 cases per 100,000. population, more than a thousand new diseases are diagnosed every day, and between a dozen and a few dozen people die from the disease every day. Although the situation regarding the use of hospital beds has stabilized, it is worrying that more and more young people with COVID-19 are entering hospitals.
SAM emphasized that a recent study in Ireland shows that 1 million Vaxzevria vaccinated population has between 4 and 10 extremely rare side effects and one death. In Lithuania, 270 thousand people were vaccinated with this vaccine. population, the number of potentially extremely rare effects is correspondingly less.
SAM continues to recommend a 12-week interval between the first and second doses of Vaxzevria. Studies have shown that after a long rest, more antibodies are formed and a stronger immunity is formed in the human body, thus ensuring the maximum benefit from the vaccine.
If a longer pause adversely affects a person’s performance, the vaccination center may administer a second dose of Vaxzevria earlier, at 4 to 12 week intervals, as recommended by the manufacturer. However, residents are urged to objectively assess the need to shorten the time between the first and second doses and choose the solution most beneficial to their health, according to the press release.
He decided to vaccinate the youngest.
The Ministry of Health (SAM) has decided not to vaccinate younger people with AstraZeneca’s COVID-19 vaccines, the BNS wrote.
On Monday, Rugilė Pilvinienė, Senior Advisor to the Pharmacovigilance and Poisoning Information Division of the State Medicines Control Agency (VVKT), announced that the first two cases of unusual blood clots had been recorded in Lithuania for people vaccinated with AstraZeneca.
“Thrombocytopenia with thrombosis, namely sagittal sinus thrombosis (the sagittal sinus is a very large vein in the brain) was two cases. Both cases for young people are 27 and 30 years old,” he said.
According to R. Pilvinienė, one person has already recovered, another is still receiving treatment in the hospital. A spokeswoman for the Drug Control Service also said that several more cases of thrombosis were recorded in April.
The European Medicines Agency (EMA) stated in early April that abnormal blood clots should be labeled a “very rare” side effect of AstraZeneca’s coronavirus vaccine.
According to the EVA, the benefits of AstraZeneca increase with the age of the vaccinated people and the deterioration of the epidemiological situation in the countries.
However, vaccination of younger people ages 20-29 and 30-39 can be reconsidered in light of national morbidity, hospital treatment, and the availability of other vaccines.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to cite DELFI as the source.
[ad_2]
